India, June 24 -- MoonLake Immunotherapeutics (MLTX) has priced an upsized $200 million public offering as the company moves to accelerate development and potential commercialization activities for its lead inflammatory disease candidate, Sonelokimab.
MoonLake will sell 9,000,000 Class A ordinary shares at $20.00 per share, along with pre-funded warrants for up to 1,000,000 additional shares priced at $19.9999 per warrant, reflecting the $0.0001 exercise price per share. The pre-funded warrants are exercisable immediately.
Gross proceeds are expected to total approximately $200 million before underwriting discounts, commissions, and offering expenses. Underwriters also have a 30-day option to purchase up to 1,500,000 additional shares at ...